194 related articles for article (PubMed ID: 30422238)
61. Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia.
Evans D; Aberle J; Beil FU
Atherosclerosis; 2011 Dec; 219(2):715-20. PubMed ID: 21993410
[TBL] [Abstract][Full Text] [Related]
62. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
63. Relationship between the distribution of plasma HDL subclasses and the polymorphisms of APOA5 in hypertriglyceridemia.
Long S; Chen Z; Han Y; Christopher DM; Zhang C; Yang Y; Tian Y
Clin Biochem; 2013 Jun; 46(9):733-9. PubMed ID: 23499587
[TBL] [Abstract][Full Text] [Related]
64. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.
Talmud PJ; Hawe E; Martin S; Olivier M; Miller GJ; Rubin EM; Pennacchio LA; Humphries SE
Hum Mol Genet; 2002 Nov; 11(24):3039-46. PubMed ID: 12417525
[TBL] [Abstract][Full Text] [Related]
65. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.
Dallongeville J; Cottel D; Montaye M; Codron V; Amouyel P; Helbecque N
Int J Cardiol; 2006 Jan; 106(2):152-6. PubMed ID: 16321685
[TBL] [Abstract][Full Text] [Related]
66. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
[TBL] [Abstract][Full Text] [Related]
67. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
68. [Apolipoprotein A5 gene: association with triglyceride metabolism and cardiovascular disease].
Oliveira Sousa M; Alía P; Pintó X
Med Clin (Barc); 2008 May; 130(20):787-93. PubMed ID: 18579034
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Cayrol F; Revuelta MV; Debernardi M; Paulazo A; Phillip JM; Zamponi N; Sterle H; Díaz Flaqué MC; Magro C; Marullo R; Mulvey E; Ruan J; Cremaschi GA; Cerchietti L
Mol Cancer Ther; 2022 Sep; 21(9):1485-1496. PubMed ID: 35793463
[TBL] [Abstract][Full Text] [Related]
70. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
71. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.
Fujimura T; Sato Y; Tanita K; Amagai R; Shimauchi T; Ogata D; Fukushima S; Miyashita A; Fujisawa Y; Kambayashi Y; Aiba S
J Dermatol; 2020 Jun; 47(6):636-640. PubMed ID: 32207181
[TBL] [Abstract][Full Text] [Related]
72. Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage.
Jiang Y; Ma J; Li H; Liu Y; You C
Lipids Health Dis; 2015 May; 14():48. PubMed ID: 25994187
[TBL] [Abstract][Full Text] [Related]
73. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
74. Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
Perera SD; Hegele RA
Curr Opin Lipidol; 2024 Apr; 35(2):66-77. PubMed ID: 38117614
[TBL] [Abstract][Full Text] [Related]
75. Gender- and obesity-specific effect of apolipoprotein C3 gene (APOC3) -482C>T polymorphism on triglyceride concentration in Turkish adults.
Coban N; Onat A; Guclu-Geyik F; Komurcu-Bayrak E; Sansoy V; Hergenc G; Can G; Erginel-Unaltuna N
Clin Chem Lab Med; 2011 Oct; 50(2):285-92. PubMed ID: 22004016
[TBL] [Abstract][Full Text] [Related]
76. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
77. Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia.
Lee MJ; Chien KL; Chen MF; Stephenson DA; Su TC
Clin Chim Acta; 2013 Feb; 416():31-5. PubMed ID: 23178747
[TBL] [Abstract][Full Text] [Related]
78. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men.
Baum L; Tomlinson B; Thomas GN
Clin Genet; 2003 May; 63(5):377-9. PubMed ID: 12752569
[TBL] [Abstract][Full Text] [Related]
79. A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug.
Bogari NM; Aljohani A; Amin AA; Al-Allaf FA; Dannoun A; Taher MM; Elsayed A; Rednah DI; Elkhatee O; Porqueddu M; Alamanni F; Khogeer SAA; Fawzy A
BMC Cardiovasc Disord; 2019 Jan; 19(1):2. PubMed ID: 30606120
[TBL] [Abstract][Full Text] [Related]
80. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
